4/A: Citius Oncology Director Granted 300,000 RSUs

Citius Oncology, Inc. Director Eugene Myron Holuka was granted 300,000 restricted stock units, vesting fully on the third anniversary of the grant date.

Summary

• Eugene Myron Holuka, a Director of Citius Oncology, Inc. (CTOR), was granted 300,000 shares of Common Stock in the form of restricted stock units (RSUs).
• The transaction date for this grant was September 19, 2025.
• The acquisition price for these securities was $0 per share, which is typical for RSU grants.
• Following this transaction, Holuka beneficially owns 300,000 shares of Common Stock.
• The restricted stock units will vest in full on the third anniversary of the grant date, which is September 19, 2028.
• Vesting is contingent upon Holuka's continuous service to Citius Oncology, Inc. or a related entity as of the applicable vesting date.

Sentiment

Score: 6

Explanation: This is a routine compensation disclosure that aligns director interests with shareholders, indicating stability in governance rather than a significant operational or financial catalyst.

Positives

• The grant of restricted stock units aligns the director's long-term interests with those of the shareholders, promoting sustained commitment to the company's performance.
• Equity compensation is a standard practice for attracting and retaining qualified directors.

Negatives

• The shares have no immediate cash value and are subject to a three-year vesting period, meaning the director does not fully own them until September 19, 2028.
• Potential future dilution for existing shareholders upon the vesting of these units.

Risks

• The vesting of the restricted stock units is subject to the reporting person's continuous service to Citius Oncology, Inc. or a related entity, meaning the shares could be forfeited if service is terminated before the vesting date.

Future Outlook

The restricted stock units are scheduled to vest in full on September 19, 2028, contingent on the director's continuous service to the company.

Industry Context

The grant of restricted stock units to a director is a common form of equity compensation in the biotechnology and pharmaceutical industries, used to incentivize long-term performance and align leadership interests with shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard practice for public companies across various industries, including biotechnology, to provide long-term incentives and align the interests of directors with those of shareholders.
• The three-year vesting schedule is a typical timeframe for such equity awards, comparable to similar compensation structures observed at peer companies in the life sciences sector.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Director Eugene Myron Holuka constitutes a related party transaction, which is a standard form of compensation for directors.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through aligned director incentives, balanced against future dilution upon vesting of the shares.
• Director (Eugene Myron Holuka): Receives a significant equity stake, incentivizing long-term commitment and performance.

Next Steps

• The restricted stock units will vest on September 19, 2028, assuming continuous service.

Key Dates

Recommendation

This Form 4/A filing details a routine grant of restricted stock units to a director, which is a standard compensation practice aimed at aligning director interests with shareholders. It does not contain information significant enough to alter an investment thesis or warrant a change in recommendation based solely on this disclosure.

Keywords

Citius Oncology, CTOR, Eugene Myron Holuka, Form 4, Restricted Stock Units, RSU, Director, Equity Compensation, Stock Grant, Insider Transaction